Key features and details | |
Cat. No. | MABL-2625 |
Name | Anti-PCSK9 mAbs |
Clone No. | AFD- FAP2M21 |
From | Recombinant Antibody |
Isotype | Engineer antibody |
Application | BLI, functional assay, inhibit, therapeutic, Block, ELISA, FC, IF |
Species Reactivity | Human |
Basic Information | |
Specificity | This antibody specifically binds the module 2 (amino acid residues 530-605) of the C-terminal domain (CTD) of PCSK9. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a serine protease enzyme encoded by the PCSK9 gene in humans and it plays a role in regulation of circulating cholesterol. It is associated with autosomal dominant hypercholesterolemia, a state of elevated levels of LDL (low-density lipoprotein) cholesterol. Autosomal dominant hypercholesterolemia can result in severe implications such as stroke and coronary heart disease. |
Alternative Name | NARC1; NARC-1; PC9; Proprotein convertase subtilisin/kexin type; Neural apoptosis-regulated convertase 1; Proprotein convertase 9; Subtilisin/kexin-like protease PC9 |
UniProt | Q8NBP7 |
Immunogen | The original antibody was generated by panning a fully human scFv phage display library with recombinant human PCSK9. Later on the scFv was transformed into a full length IgG antibody. |
Application Notes | This antibody binds human PCSK9 with an extremely slow dissociation rate constant and exert its hypolipidemic effect by blocking PCSK9-LDLR interaction. The binding characterization of this antibody was done using ELISA. Bio-Layer Interferometry (BLI) analysis revealed that the full-length IgG1 antibody FAP2M21 binds to hPCSK9 with a KD as low as 1.42 nM, and a dramatically slow dissociation rate (koff, 4.68 × 10−6 s−1) (PMID: 33647772). This antibody was also used to analyze LDLR expressed on the surface of HepG2 cells using flow cytometry and immunofluorescence staining. This antibody potently inhibited PCSK9-induced reduction of LDL-C uptake in HepG2 cells, with an EC50 of 43.56 nM. |
Antibody First Published | Xu et al. Development of a novel, fully human, anti-PCSK9 antibody with potent hypolipidemic activity by utilizing phage display-based strategy. EBioMedicine. 2021 Mar;65:103250. PMID:33647772 |
Note on publication | Describes the generation of this antibody using phage display technology. |
COA Information （For reference only, actual COA shall prevail） | |
Size | 100 μg Purified antibody. |
Concentration | 1 mg/ml. |
Purification | Protein A affinity purified |
Buffer | PBS with 0.02% Proclin 300. |
Concentration | 1 mg/ml. |
Storage Recommendation | Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at - 20⁰C. |
